1.Clinical characteristics and prognosis of male dermatomyositis patients with positive anti-melanoma differentiation associated gene 5 antibody
Yitian SHI ; Fenghong YUAN ; Ting LIU ; Wenfeng TAN ; Ju LI ; Min WU ; Zhanyun DA ; Hua WEI ; Lei ZHOU ; Songlou YIN ; Jian WU ; Yan LU ; Dinglei SU ; Zhichun LIU ; Lin LIU ; Longxin MA ; Xiaoyan XU ; Yinshan ZANG ; Huijie LIU ; Tianli REN
Chinese Journal of Rheumatology 2024;28(1):44-49
		                        		
		                        			
		                        			Objective:To investigate the clinical features and prognosis of male with anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody.Methods:The clinical data of 246 patients with DM and anti-MDA5 autoantibodies hospitalized by Jiangsu Myositis Cooperation Group from 2017 to 2020 were collected and retrospectively analyzed. Chi-square test was performed to compared between counting data groups; Quantitative data were expressed by M ( Q1, Q3), and rank sum test was used for comparison between groups; Single factor survival analysis was performed by Kaplan-Meier method and Log rank test; Cox regression analysis were used for multivariate survival analysis. Results:①The male group had a higher proportion of rash at the sun exposure area [67.1%(47/70) vs 52.8%(93/176), χ2=4.18, P=0.041] and V-sign [50.0%(35/70) vs 30.7%(54/176), χ2=8.09, P=0.004] than the female group. The male group had higher levels of creatine kinase [112(18, 981)U/L vs 57 (13.6, 1 433)U/L, Z=-3.50, P<0.001] and ferritin [1 500 (166, 32 716)ng/ml vs 569 (18, 14 839)ng/ml, Z=-5.85, P<0.001] than the female group. The proportion of ILD [40.0%(28/70) vs 59.7%(105/176), χ2=7.82, P=0.020] patients and the red blood cell sedimentation rate[31.0(4.0, 101.5)mm/1 h vs 43.4(5.0, 126.5)mm/1 h, Z=-2.22, P=0.026] in the male group was lower than that of the female group, but the proportion of rapidly progressive interstitial lung disease (PR-ILD) [47.1%(33/70) vs 31.3%(55/176), χ2=5.51, P=0.019] was higher than that of the female group. ②In male patients with positive anti-MDA5 antibodies,the death group had a shorter course of disease[1.0(1.0, 3.0) month vs 2.5(0.5,84) month, Z=-3.07, P=0.002], the incidence of arthritis [16.7%(4/24) vs 42.2%(19/45), χ2=4.60, P=0.032] were low than those in survival group,while aspartate aminotransferase (AST)[64(22.1, 565)U/L vs 51(14,601)U/L, Z=-2.42, P=0.016], lactate dehydrogenase (LDH) [485(24,1 464)U/L vs 352(170, 1 213)U/L, Z=-3.38, P=0.001], C-reactive protein (CRP) [11.6(2.9, 61.7) mg/L vs 4.95(0.6, 86.4) mg/L, Z=-1.96, P=0.050], and ferritin levels [2 000(681, 7 676) vs 1 125 (166, 32 716)ng/ml, Z=-3.18, P=0.001] were higher than those in the survival group, and RP-ILD [95.8%(23/24) vs 22.2%(10/45), χ2=33.99, P<0.001] occurred at a significantly higher rate. ③Cox regression analysis indicated that the course of disease LDH level, and RP-ILD were related factors for the prognosis of male anti-MDA5 antibodies [ HR (95% CI)=0.203(0.077, 0.534), P=0.001; HR (95% CI)=1.002(1.001, 1.004), P=0.003; HR (95% CI)=95.674 (10.872, 841.904), P<0.001]. Conclusion:The clinical manifestations of male anti-MDA5 antibody-positive patients are different from those of female. The incidence of ILD is low, but the proportion of PR-ILD is high. The course of disease, serum LDH level, and RP-ILD are prognostic factors of male anti-MDA5 antibody-positive patients.
		                        		
		                        		
		                        		
		                        	
		                				2.Two new ursane triterpenoids from Agastache rugosa  (Fisch. et.Mey.) O. Kuntze
		                			
		                			Ya-ting REN ; Bei LI ; Jie MA ; Yu-huan LI ; Ying-da ZANG ; Chuang-jun LI ; Dong-ming ZHANG
Acta Pharmaceutica Sinica 2023;58(6):1650-1654
		                        		
		                        			
		                        			 Two new ursane triterpenoids along with twelve known compounds were isolated from 80% ethanol extract of 
		                        		
		                        	
		                				3.Three new anthraquinones from Prismatomeris tetrandra  (Roxb.) K. Schum and their protective effects in neuroblastoma cells
		                			
		                			Xin-yi CHEN ; Chen ZHANG ; Yi-rong DONG ; Ying-da ZANG ; Jia-qi CHEN ; Hong-tao JIN ; Dong-ming ZHANG
Acta Pharmaceutica Sinica 2023;58(12):3710-3714
		                        		
		                        			
		                        			 Three new anthraquinones were isolated from the 80% ethanol extract of 
		                        		
		                        	
		                				4.Two new labdane diterpenoids from the leaves of Callicarpa formosana  Rolfe
		                			
		                			Pan-pan GAO ; Ya-ting REN ; Jie MA ; Ying-da ZANG ; Jing-zhi YANG ; Dan ZHANG ; Chuang-jun LI ; Dong-ming ZHANG
Acta Pharmaceutica Sinica 2022;57(5):1448-1451
		                        		
		                        			
		                        			 Two new labdane diterpenoids were isolated from 95% ethanol extract of the leaves of
		                        		
		                        	
5.Pancreatic lipase inhibitory constituents from Fructus Psoraleae.
Xu-Dong HOU ; Li-Lin SONG ; Yun-Feng CAO ; Yi-Nan WANG ; Qi ZHOU ; Sheng-Quan FANG ; Da-Chang WU ; Shi-Zhu ZANG ; Lu CHEN ; Yue BAI ; Guang-Bo GE ; Jie HOU
Chinese Journal of Natural Medicines (English Ed.) 2020;18(5):369-378
		                        		
		                        			
		                        			Pancreatic lipase (PL), a crucial enzyme in the digestive system of mammals, has been proven as a therapeutic target to prevent and treat obesity. The purpose of this study is to evaluate and characterize the PL inhibition activities of the major constituents from Fructus Psoraleae (FP), one of the most frequently used Chinese herbs with lipid-lowering activity. To this end, a total of eleven major constituents isolated from Fructus Psoraleae have been obtained and their inhibition potentials against PL have been assayed by a fluorescence-based assay. Among all tested compounds, isobavachalcone, bavachalcone and corylifol A displayed strong inhibition on PL (IC < 10 μmol·L). Inhibition kinetic analyses demonstrated that isobavachalcone, bavachalcone and corylifol A acted as mixed inhibitors against PL-mediated 4-methylumbelliferyl oleate (4-MUO) hydrolysis, with the K values of 1.61, 3.77 and 10.16 μmol·L, respectively. Furthermore, docking simulations indicated that two chalcones (isobavachalcone and bavachalcone) could interact with the key residues located in the catalytic cavity of PL via hydrogen binding and hydrophobic interactions. Collectively, these finding provided solid evidence to support that Fructus Psoraleae contained bioactive compounds with lipid-lowering effects via targeting PL, and also suggested that the chalcones in Fructus Psoraleae could be used as ideal leading compounds to develop novel PL inhibitors.
		                        		
		                        		
		                        		
		                        	
		                				6.A new carbazole alkaloid from the stems of Clausena lansium 
		                			
		                			Jie MA ; Xing-yan SUN ; Ying-da ZANG ; Jian-zhou MENG ; Chuang-jun LI ; Jing-zhi YANG ; Dong-ming ZHANG
Acta Pharmaceutica Sinica 2020;55(1):110-112
		                        		
		                        			
		                        			 A new carbazole alkaloid was isolated from the aqueous extract of the stems of 
		                        		
		                        	
7.Infrapyloric lymph node metastasis pattern in middle/lower gastric cancer: an exploratory analysis of a multicenter prospective observational study (IPA-ORIGIN).
Tasiken BAHETI ; Ru-Lin MIAO ; Gang ZHAO ; Da-Guang WANG ; Feng-Lin LIU ; Jiang YU ; Shuang-Yi REN ; Kai YE ; Su YAN ; Kun YANG ; Wei-Dong ZANG ; Lin FAN ; Bin LIANG ; Jun CAI ; Wei-Hua FU ; Wei WANG ; Zheng-Rong LI ; Zhao-Jian NIU ; Jun YOU ; Xing-Feng QIU ; Wu SONG ; Lu ZANG
Chinese Medical Journal 2020;133(22):2759-2761
8.Application of artificial ligament in treatment of lower abdominal wall reconstruction after pubic tumor resection.
Jie ZANG ; Wei GUO ; Xiao Dong TANG ; Hua Yi QU ; Da Sen LI
Journal of Peking University(Health Sciences) 2018;50(6):1049-1052
		                        		
		                        			OBJECTIVE:
		                        			For patients who had hemipelvectomies involving the resection of a portion or the whole of the pubis, bony reconstruction was not recommended commonly. However, the soft tissue reconstruction of the lower abdominal wall may benefit these patients. The object of the study was to determine the clinical effect of lower abdominal wall reconstruction with LARS ligament after pubic tumor resection interms of patient-reported and objective outcome.
		                        		
		                        			METHODS:
		                        			In this series, we reviewed twenty-five patients who underwent pubic tumor resection followed by reconstruction with LARS ligament between February 2012 and February 2018 retrospectively. We evaluated the clinical outcome and complication of this surgical treatment. The function outcome was evaluated according the musculoskeletal tumor society scores (MSTS) for all the patients at the end of the last follow-up.
		                        		
		                        			RESULTS:
		                        			All the patients were stable during the surgery. There were eight patients who underwent resection of superior ramus of pubis, five patients who had resection of inferior ramus of pubis, and twelve patients who received both superior and inferior ramus of pubis. For all the patients, the mean blood loss was (774±580) mL. The mean operation time was (138±25) min. The mean hospital stay was (19±6) d. For the patients who had resection of superior ramus, inferior ramus, as well as both superior and inferior ramus, the mean blood loss were (763±802) mL, (730±315) mL and (808±485) mL, respectively. The mean operation time were (133±27) min, (135±35) min and (143±20) min, respectively. The mean hospital stay were (18±5) d, (22±9) d and (19±6) d, respectively. The mean follow-up time was (37±21) months. Local recurrence was observed in one patient with chondrosarcoma. One patient with renal cancer metastasis died of the disease. No ligament infection, ligament related complication and incisional hernias were observed. Twenty-three patients could ambulate without assistive devices, and the remaining two could walk by crutches. Postoperative pain was reported as none in nineteen patients, mild in three, and moderate in three. From a functional point, the mean MSTS score was 87±4.
		                        		
		                        			CONCLUSION
		                        			Lower abdominal wall reconstruction with LARS ligament after pubic tumor resection could have satisfactory clinical outcome. It could prevent the occurrence of herniation, decrease the infection rate by minishing the dead space, and achieve good patient-reported outcome.
		                        		
		                        		
		                        		
		                        			Abdominal Wall
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Ligaments
		                        			;
		                        		
		                        			Neoplasm Recurrence, Local
		                        			;
		                        		
		                        			Prostheses and Implants
		                        			;
		                        		
		                        			Pubic Bone/surgery*
		                        			;
		                        		
		                        			Reconstructive Surgical Procedures
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
9.Basal Forebrain Cholinergic Deficits Reduce Glucose Metabolism and Function of Cholinergic and GABAergic Systems in the Cingulate Cortex.
Da Un JEONG ; Jin Hwan OH ; Ji Eun LEE ; Jihyeon LEE ; Zang Hee CHO ; Jin Woo CHANG ; Won Seok CHANG
Yonsei Medical Journal 2016;57(1):165-172
		                        		
		                        			
		                        			PURPOSE: Reduced brain glucose metabolism and basal forebrain cholinergic neuron degeneration are common features of Alzheimer's disease and have been correlated with memory function. Although regions representing glucose hypometabolism in patients with Alzheimer's disease are targets of cholinergic basal forebrain neurons, the interaction between cholinergic denervation and glucose hypometabolism is still unclear. The aim of the present study was to evaluate glucose metabolism changes caused by cholinergic deficits. MATERIALS AND METHODS: We lesioned basal forebrain cholinergic neurons in rats using 192 immunoglobulin G-saporin. After 3 weeks, lesioned animals underwent water maze testing or were analyzed by 18F-2-fluoro-2-deoxyglucose positron emission tomography. RESULTS: During water maze probe testing, performance of the lesioned group decreased with respect to time spent in the target quadrant and platform zone. Cingulate cortex glucose metabolism in the lesioned group decreased, compared with the normal group. Additionally, acetylcholinesterase activity and glutamate decarboxylase 65/67 expression declined in the cingulate cortex. CONCLUSION: Our results reveal that spatial memory impairment in animals with selective basal forebrain cholinergic neuron damage is associated with a functional decline in the GABAergic and cholinergic system associated with cingulate cortex glucose hypometabolism.
		                        		
		                        		
		                        		
		                        			Acetylcholine/metabolism
		                        			;
		                        		
		                        			Alzheimer Disease
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Antibodies, Monoclonal/*pharmacology
		                        			;
		                        		
		                        			Basal Forebrain/*drug effects/metabolism
		                        			;
		                        		
		                        			Cholinergic Agents/administration & dosage/*pharmacology
		                        			;
		                        		
		                        			Cholinergic Neurons/*drug effects/metabolism
		                        			;
		                        		
		                        			Fluorodeoxyglucose F18
		                        			;
		                        		
		                        			GABAergic Neurons/*drug effects/metabolism
		                        			;
		                        		
		                        			Glucose/*metabolism
		                        			;
		                        		
		                        			Gyrus Cinguli/*drug effects/metabolism
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Injections
		                        			;
		                        		
		                        			Maze Learning
		                        			;
		                        		
		                        			Motor Activity/physiology
		                        			;
		                        		
		                        			Positron-Emission Tomography
		                        			;
		                        		
		                        			Rats
		                        			;
		                        		
		                        			Ribosome Inactivating Proteins, Type 1/*pharmacology
		                        			
		                        		
		                        	
10.Derivatization of berberine based on its synergistic antifungal activity with fluconazole against fluconazole-resistant Candida albicans.
Shu-Juan TIAN ; Yue GAO ; Cheng-Xu ZANG ; Zhan CAI ; Ting-jun-hong NI ; Shan-Lun TAN ; Yong-Bing CAO ; Yuan-Ying JIANG ; Da-Zhi ZHANG
Acta Pharmaceutica Sinica 2014;49(11):1563-1568
		                        		
		                        			
		                        			Abstract: Our previous work revealed berberine can significantly enhance the susceptibility of fluconazole against fluconazole-resistant Candida albicans, which suggested that berberine has synergistic antifungal activity with fluconazole. Preliminary SAR of berberine needs to be studied for the possibility of investigating its target and SAR, improving its drug-likeness, and exploring new scaffold. In this work, 13-substitutited benzyl berberine derivatives and N-benzyl isoquinoline analogues were synthesized and characterized by 1H NMR and MS. Their synergetic activity with fluconazole against fluconazole-resistant Candida albicans was evaluated in vitro. The 13-substitutited benzyl berberine derivatives 1a-1e exhibited comparable activity to berberine, which suggested that the introduction of functional groups to C-13 can maintain its activity. The N-benzyl isoquinolines, which were designed as analogues of berberine with its D ring opened, exhibited lower activity than berberine. However, compound 2b, 2c, and 4b showed moderate activity, which indicated that berberine may be deconstructed to new scaffold with synergistic antifungal activity with fluconazole. The results of our research may be helpful to the SAR studies on its other biological activities.
		                        		
		                        		
		                        		
		                        			Antifungal Agents
		                        			;
		                        		
		                        			pharmacology
		                        			;
		                        		
		                        			Berberine
		                        			;
		                        		
		                        			pharmacology
		                        			;
		                        		
		                        			Candida albicans
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			Drug Resistance, Fungal
		                        			;
		                        		
		                        			Drug Synergism
		                        			;
		                        		
		                        			Fluconazole
		                        			;
		                        		
		                        			pharmacology
		                        			;
		                        		
		                        			Isoquinolines
		                        			;
		                        		
		                        			pharmacology
		                        			;
		                        		
		                        			Microbial Sensitivity Tests
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail